Nutriband Issues Letter to Shareholders CEO Publishes Letter to Shareholders looking over achievements in 2024 and outlook for 2025

Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology Chinese Patent for AVERSA extended to Macao

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 Nutriband Inc. Q3 report and highlights

Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th Serguei Melnik will present at the Noble Conference to discuss the companies latest advances with its AVERSA technology

Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology Nutriband Inc receives Hong Kong Patent Notice of Publication for its AVERSA patent application bringing the total number of countries covered to 46